Arcutis Q4 ZORYVE revenue $69.4M (+413% YoY); net loss narrows to $10.8M

Arcutis Biotherapeutics, Inc.

2024-FY EPS reported -$1.16 revenue$196,542,000

Q4 total revenue $71.4M vs $13.5M YoY; net loss $0.09/share vs $0.72/share prior year.
Full-year ZORYVE net product revenue $166.5M (+471% YoY); ZORYVE is #1 branded non-steroidal topical in U.S.
Submitted sNDA for ZORYVE cream 0.05% for atopic dermatitis in children ages 2-5; target action Q4 2025.
Prepaid $100M of $200M term loan; maintains ability to re-draw; cash & securities $228.6M at year-end.
ZORYVE foam for scalp/body psoriasis PDUFA date May 22, 2025; partnered with Odell Beckham Jr. for seborrheic dermatitis awareness.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.